Neurocrine Biosciences, Inc. (NBIX)
169.40
-5.01
(-2.87%)
USD |
NASDAQ |
Nov 12, 16:00
169.47
+0.07
(+0.04%)
After-Hours: 20:00
Neurocrine Biosciences Price to Book Value : 4.424 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 4.424 |
| November 11, 2026 | 4.555 |
| November 10, 2026 | 4.417 |
| November 09, 2026 | 4.410 |
| November 06, 2026 | 4.300 |
| November 05, 2026 | 4.172 |
| November 04, 2026 | 4.337 |
| November 03, 2026 | 4.305 |
| November 02, 2026 | 3.796 |
| October 30, 2026 | 3.816 |
| October 29, 2026 | 3.823 |
| October 28, 2026 | 3.801 |
| October 27, 2026 | 3.813 |
| October 26, 2026 | 3.810 |
| October 23, 2026 | 3.727 |
| October 22, 2026 | 3.742 |
| October 21, 2026 | 3.691 |
| October 20, 2026 | 3.709 |
| October 19, 2026 | 3.578 |
| October 16, 2026 | 3.544 |
| October 15, 2026 | 3.577 |
| October 14, 2026 | 3.550 |
| October 13, 2026 | 3.529 |
| October 12, 2026 | 3.692 |
| October 09, 2026 | 3.720 |
| Date | Value |
|---|---|
| October 08, 2026 | 3.689 |
| October 07, 2026 | 3.747 |
| October 06, 2026 | 3.800 |
| October 05, 2026 | 3.766 |
| October 02, 2026 | 3.739 |
| October 01, 2026 | 3.675 |
| September 30, 2026 | 3.704 |
| September 29, 2026 | 3.806 |
| September 28, 2026 | 3.863 |
| September 25, 2026 | 3.807 |
| September 24, 2026 | 3.822 |
| September 23, 2026 | 3.837 |
| September 22, 2026 | 3.913 |
| September 21, 2026 | 3.960 |
| September 18, 2026 | 4.022 |
| September 17, 2026 | 4.176 |
| September 16, 2026 | 4.112 |
| September 15, 2026 | 4.127 |
| September 14, 2026 | 4.325 |
| September 11, 2026 | 4.297 |
| September 10, 2026 | 4.307 |
| September 09, 2026 | 4.267 |
| September 08, 2026 | 4.267 |
| September 04, 2026 | 4.281 |
| September 03, 2026 | 4.356 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 17.60 |
| Halozyme Therapeutics, Inc. | -- |
| BioCryst Pharmaceuticals, Inc. | -- |
| Iovance Biotherapeutics, Inc. | 4.343 |
| Precigen, Inc. | 19.94 |
Price to Book Value Related Metrics
| PE Ratio | 25.12 |
| PS Ratio | 4.765 |
| PEG Ratio | 0.4112 |
| Price to Free Cash Flow | 18.13 |
| Price | 169.40 |
| Earnings Yield | 3.98% |
| Market Cap | 17.16B |
| PEGY Ratio | 0.4112 |
| Operating PE Ratio | 19.39 |
| Normalized PE Ratio | 23.39 |